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Figure S1 (related to Figure 1). Patient-derived hiPSCs and hCOs. 
 (A) Representative images of hiPSCs immunolabeled for pluripotency markers OCT4A, 
NANOG, and SOX2. Scale bars: 50 µm. (B) Representative bright-field images of hCOs at 16, 
35 and 56DIV. Scale bars: 1 mm. (C-D) Quantification of surface areas of hCOs at (C) 16DIV 
and (D) 84DIV. (E) Representative immunofluorescence images of 16DIV CTL (CTL1), TGD 
(TGD1) and aTGD hCOs immunolabeled for dorsal forebrain (PAX6, OTX2), midbrain (OTX2, 
EN1) and hindbrain (GBX2) markers. Scale bars: 50 µm. (F) (related to Figure 1I) Quantitation 
of SMI-32+ immunopositive dendrites in 35DIV TGD relative to CTL hCOs. (G) Representative 
images of 35DIV CTL and TGD hCOs immunolabeled for early-stage immature neurons 
(NeuroD1) and deep-layer cortical neurons (TBR1) and quantification of the number of TBR1+ 
deep-layer neurons per image field in hCOs at 35DIV. (H) Representative images of 84DIV CTL 
and TGD hCOs immunolabeled for deep-layer (TBR1) and upper-layer (SATB2) neurons and 
quantification of %SATB2+ upper-layer neurons in hCOs at 84DIV. Scale bars, 100 µm. 
Independent hiPSC lines representing three different CTL or TGD lines (black, CTL1 / TGD1; 
white, CTL2 / TGD2; red, CTL3 / TGD3) are shown. Data are expressed as the mean ± SEM. 
Each data point represents one hCO, 2-6 hCOs per experimental replicate, 3-5 experimental 
replicates per genotype. Statistical analysis by unpaired, two-tailed t-test or one-way ANOVA 
with Bonferroni multiple comparisons test.   
 
Figure S2 (related to Figure 1). Neuronal differentiation defects in TGD and intragenic 
NF1-mutant hCOs. 
(A) %EdU+ neural stem cells (NSCs) in 16DIV CTL and TGD hCOs. (B) Quantification of late-
stage immature (NeuN+) neurons per image field in the SVZ of intragenic NF1-mutant hCOs 
relative to CTL hCOs at 35DIV. (C) Representative images and quantification of CTL and TGD 
hCOs immunolabeled for TUNEL (green) and NeuroD1 (red) (co-localization indicated by white 
arrows) at 56DIV. (A-C) Independent hiPSC lines (black, CTL1 / TGD1; white, CTL2 / TGD2; 
red, CTL3 / TGD3) are shown. (D-E) Representative images of CTL and TGD hCOs 
immunolabeled for MAP2+ and SMI-32+ dendrites at (D) 56DIV and (E) 84DIV. (F) 
Representative control (CTL1) and intragenic NF1-mutant hCOs immunolabeled for dendrite-
specific markers (MAP2+, SMI-32+) at 35DIV. Data are shown as the mean ± SEM. Each data 
point represents one biological replicate (hCO), 2-6 biological replicates per experimental 
replicate, 3-5 experimental replicates per genotype. Statistical analysis by unpaired, two-tailed t-
test or one-way ANOVA with Dunnett’s multiple comparisons test. Scale bars: 50 µm. 
  
 
Figure S3 (related to Figure 2 and 3). RAS activity and differential gene expression 
analysis of TGD and CTL hCOs. 
(A) RAS activation in CTL and TGD 8DIV embryoid bodies and 16DIV hCOs. (B-C) Reduced 
RAS activity in (B) TGD3 and aTGD 16DIV hCOs and (C) CTL1 and CTL2 hCOs following 10 
µM pan-RAS-IN-1 (IN-1) treatment. The mean CTL hCO RAS activity was assigned a value of 1 
(dotted line). (A-C) Each data point represents an independent experimental replicate consisting 
of 20 pooled embryoid bodies or 4 pooled hCOs. Statistical analysis by unpaired, two-tailed t-
test or one-way ANOVA with Dunnett’s multiple comparisons. (D) Quantification of NSC 
proliferation (fold change in %Ki67+ NSCs) in control hCOs at 16DIV with or without IN-1 
treatment. Each data point represents one hCO, 2-6 hCOs per experimental replicate, 3-5 
experimental replicates per genotype. Statistical analysis by unpaired, two-tailed t-test. (E) 
Number of early-stage immature (NeuroD1+) neurons per image field in the SVZ of 16DIV TGD3 
and aTGD hCOs with and without IN-1 treatment. Each data point represents one hCO, 3-12 
hCOs per clone. Statistical analysis by unpaired, two-tailed t-test comparing TGD3 and aTGD 
hCOs with control values (indicated by dotted line). (A-E) All data are shown as the mean ± 
SEM. Independent (A, E) hiPSC lines (black, CTL1 / TGD1 / aTGD1; white, CTL2 / TGD2 / 
aTGD2; red, CTL3 / TGD3, aTGD-3), or (C-D) independent hiPSC clones (black, clone 1; white, 
clone 2; red, clone 3) are shown. (F) Representative images of 16DIV TGD3 and aTGD hCOs 
with and without RAS-IN-1 treatment immunolabeled for MAP2+ dendrites. Scale bars: 50 µm. 
(G) mRNA expression of RAB11FIP4 in 56DIV hCOs showing gene deletion status in TGD1-3 
and aTGD. Statistical analysis by unpaired, two-tailed t-test. (H) RT-qPCR analysis of 
microRNA gene expression in CTL hCOs at the time point of highest expression (16DIV). 
Statistical analysis by one-way ANOVA; F-ratio / P values reported. MIR4733 was not 
expressed in CTL hCOs. Each mRNA expression data point represents one biological replicate 
(hCO), 2-3 hCOs per experimental replicate. (I) Time course analysis of mRNA expression in 
16, 35 and 56DIV CTL hCOs for 7 protein-coding genes included in differential gene expression 
analysis, illustrating highest transcript expression levels for 6 of the 7 genes at 56DIV. ATAD5 
had no change in expression over time. Each time point represents 2 independent experimental 
replicates of CTL1 hCOs with each experimental replicate containing 2 biological replicates 
(hCOs). Data are shown as the mean ± SEM. (J-N) Representative unprocessed western blots 
of CTL and TGD protein expression including (J) COPRS, (K) SUZ12, (L) ATAD5, (M) CRLF3 
and (N) UTP6.  
  
 
Figure S4 (related to Figures 3 and 4). CRLF3 sequence conservation, developmental 
expression, and downstream signaling.  
(A) Amino acid sequence alignments revealed 92.8% conservation in p.Leu389 between human 
and 303 vertebrate CRLF3 orthologs. Ten representative orthologs from NCBI’s Eukaryotic 
Genome Annotation pipeline are shown, with p.Leu389 outlined in red. (B) Heat map of CRLF3 
mRNA expression levels in the human forebrain and hindbrain at different developmental 
stages, as reported by the Expression Atlas: Human RNA-seq time-series of the development of 
seven major organs. TPM: transcripts per million. (C) Uncropped western immunoblot from 
Figure 4A. (D) Neurofibromin relative expression  in CTL, TGD, and shCRLF3 hiPSC-derived 
NSCs. Independent hiPSC lines (black, CTL1 / TGD1 / shCRLF3-1; white, CTL2 / TGD2 / 
shCRLF3-2; red, CTL3 / TGD3 / shCRLF3-3) are shown. Statistical analysis by unpaired, two-
tailed t-test. (E) Immunoblots and quantitation of neurofibromin expression in different 
subcellular fractions (cytoplasm, membrane, nucleus) in shCTL and shCRLF3 NPCs. GAPDH 
(cytoplasm), Na/K ATPase (membrane) and human-specific Ku80 (nucleus) were used as 
loading controls. (F) Immunoblot and quantitation of CRLF3 expression in NPCs harboring NF1 
point mutations, either conferring <30% reduced (Group 1), or >70% reduced (Group 2) 
neurofibromin levels, NPCs harboring homozygous null NF1 mutations (NF1-/-), or non-mutant 
controls. GAPDH was used as a loading control. (E-F) Data are expressed as the mean ± SEM. 
Statistical analysis by (E) unpaired, two-tailed t-test or (F) one-way ANOVA with Bonferroni 
post-test correction. ns, not significant. (G) Representative images of 84DIV shCTL and 
shCRLF3 hCOs immunolabeled for deep-layer (TBR1) and upper-layer (SATB2) neurons and 
quantification of %SATB2+ upper-layer neurons in hCOs at 84DIV. Scale bar: 100 µm.  (H) 
hiPSC-derived NSCs immunolabeled for NSC markers SOX2, Vimentin, Nestin and PAX6. 
Scale bar: 50µm. (I) Unprocessed western immunoblot from Figure 4H. (J) Rac1 activity levels 
in shCTL and shCRLF3 NSCs. Each data point represents individual NSC sample. Statistical 
analysis by unpaired, two-tailed t-test. (K) RhoA activity in 2DIV TGD and shCRLF3 hCOs with 
and without 1 µg/mL CN03 RhoA activator (CN03) treatment for 24 hours. Each data point 
represents 6 pooled hCOs. Statistical analysis by two-way ANOVA with Sidak’s multiple 
comparison test performed comparing untreated with treated hCOs. All data are shown as the 
mean ± SEM and the P values are shown above each bar. (L-N) Representative images of (L) 
NeuroD1+ (green)/ NeuN+ (red) neurons, (M) cleaved caspase-3+ apoptotic immature neurons 
and (N) SMI-32+ dendrites in 35DIV CTL, TGD and shCRLF3 hCOs with and without CN03 
treatment. Scale bars: 50 µm. 
Table S1 (related to Figure 1). Patient-derived CTL1-3, TGD1-3 and aTGD (atypical TGD) 
hiPSC lines and isogenic hiPSC lines CRISPR/Cas9-engineered to harbor NF1 patient NF1 
gene mutations. 
 
 aBJFF.6 commercially available 
 bDr. Matthew B. Harms (WUSM) 







Genotype Sex Age (years) Specimen source No. 
clones 
CTL1a Male Fetal Skin biopsy 2 
CTL2b Male 27 Skin biopsy 1 
CTL3c Male 41 Skin biopsy 1 
TGD1 Male 44 Skin biopsy 2 
TGD2 Male 6 Urine 2 
TGD3 Male 11 Blood 3 
aTGD Female 16 Blood 3 
NF1 patient mutation Protein level Mutation Type No. 
clones 
c.1149C>A p.Cys383X Nonsense 2 
c.1185+1G>A p.Asn355_Lys395del Splice site 2 
c.3431-32_dupGT p.Thr1145Val_FS Frameshift 2 
c.5425C>T p.Arg1809Cys Missense 2 
c.6619C>T p.Gln2207X Nonsense 1 
Table S2 (related to Figure 3). Human genomic DNA whole-exome sequencing. 
 
  
Patient ID SRS-2 Age (years) Sex CRLF3-mutation NF1-mutation 
OtB3317 81 10 M c.1166T>C  c.5305C>T  
OtC6610 48 11 F  c.3137_3138delCA 
OtB3335 64 11 M  c.1756_1759delACTA  
OtB3325 45 11 F  c.3888T>G 
OtC6607 70 11 F  c.3449C>T 
OtB3313 98 13 M c.1166T>C  c.7255_7256delCT 
OtC6614 48 13 M  c.2965G>T 
OtC6612 50 13 M c.1166T>C  c.910C>T 
OtB3333 91 13 M c.1166T>C  c.204+1G>T 
OtB3326 54 15 F c.1166T>C  c.2125T>C  
OtB3321 88 15 M  c.6855C>A  
OtB3312 98 15 M c.1166T>C  c.4514delG 
OtC6619 46 16 F  c.4006C>T 
OtC6615 76 16 M  c.205-19T>A 
OtB3319 74 16 F c.1166T>C  c.4985G>A 
OtB3323 56 17 M  c.1885G>A 
OtB3336 46 18 M  c.3520C>T  
Table S3 (related to Figure 4). Differentially expressed gene list filtered for non-significant 
genes in the comparison of TGD vs shCRLF3 samples. 
Gene symbol P value  
(TGD vs. shCRLF3) 
FDR step up  
(TGD vs. shCRLF3) 
Fold change  
(TGD vs. shCRLF3) 
KCP 0.1073 0.1689 2.99 
SPN 0.2332 0.3201 2.90 
THSD7A 0.0109 0.0248 2.84 
MMP23B 0.0177 0.0373 2.67 
ACOT11 0.0456 0.0826 2.25 
ASCL1 0.9106 0.9346 1.82 
DACT1 0.0700 0.1184 1.75 
LDHAP4 0.7063 0.7715 1.29 
ADGRE5 0.7043 0.7696 1.25 
RUBCNL 0.8635 0.8992 1.20 
NEFM 0.5160 0.6030 1.13 
EPB41L4A 0.9420 0.9570 -1.09 
TENM2 0.2461 0.3342 -1.27 
MDGA2 0.1567 0.2308 -1.27 
CAMK4 0.5252 0.6119 -1.31 
SORBS2 0.0812 0.1341 -1.64 
ATCAY 0.1408 0.2112 -1.69 
PTX3 0.0732 0.1229 -1.72 
MANEAL 0.0455 0.0825 -1.78 
ITGB8 0.0134 0.0296 -1.86 
DCLK2 0.0091 0.0214 -1.91 
SYT5 0.0236 0.0474 -2.25 
SYP 0.0102 0.0234 -2.25 
RASGRP1 0.0241 0.0481 -2.58 
MSI1 0.0047 0.0121 -2.58 
CRABP1 0.0052 0.0134 -2.82 
FCHO1 0.0056 0.0142 -2.85 
ECEL1 0.0114 0.0257 -2.90 
PLEKHA7 0.0097 0.0225 -3.02 
ULBP1 0.0051 0.0131 -3.43 
MMRN1 0.0103 0.0237 -3.89 
 
  
Table S4 (related to Figures 1-4). Summary of experimental samples, replicates and statistical 
tests used.  
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